Home » SYNCARDIA ANNOUNCES INITIAL IMPLANTATION OF THE CARDIOWEST TEMPORARY TOTAL ARTIFICIAL HEART AT THE CLEVELAND CLINIC
SYNCARDIA ANNOUNCES INITIAL IMPLANTATION OF THE CARDIOWEST TEMPORARY TOTAL ARTIFICIAL HEART AT THE CLEVELAND CLINIC
SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and mechanical circulatory support devices, announced today implantation of its CardioWest(TM) Temporary Total Artificial Heart (TAH-t) in a patient at The Cleveland Clinic. The Cleveland Clinic is the first "new" center, beyond the institutions that previously participated in the recently reported pivotal U.S. multi-center trial, to adopt this technology. The TAH-t received FDA approval allowing commercial distribution in late 2004.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May